Κατεύθυνση Ανάπτυξη Νέων Φαρμάκων: Έρευνα, Κυκλοφορία και Πρόσβαση
Library of the School of Health Sciences

2023-06-01

2023

Nitsas Apostolos

Ηλίας Κοττέας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ανδριανή Χαρπίδου, Ακαδημαϊκή Υπότροφος, Ιατρική Σχολή, ΕΚΠΑ
Γαρυφαλλιά Πουλάκου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Ο ρόλος του lobbying (πολιτικές πίεσης) στη διαπραγμάτευση και τιμολόγηση νέων φαρμάκων

Greek

The role of lobbying (politics of pressure) in negotiation and pricing of new drugs

The price regulation of pharmaceutical products in Greece is centralized.
The National Medicines Agency (NMA) is the main regulatory authority
operating under the auspices of the Ministry of Health and Social Solidarity.
According to data from the Organization for Economic Co-operation and
Development (OECD), the total per capita expenditure on pharmaceutical care
in Greece is among the lowest in Europe, representing 58% of the EU-12
average.
In 1998, Greece introduced a reimbursement list and the lowest
reference pricing system among the 15 member states of the European Union
in order to control the increase in pharmaceutical expenditure. The measures
proved ineffective, as pharmaceutical costs, after a short-term reduction,
continued to rise at rates similar to those before the introduction of price control
mechanisms. The pharmaceutical legislation, no. 3457, passed on May 8,
2006, with the aim of greater access to medicines, improving the quality of life
of citizens, the effective and efficient use of health resources, transparency in
public management, the protection of public health and the maintenance of
long-term economic sustainability of the insurance system.
The innovative aspect of the new legislation is the abolition of the
positive list and the establishment of a rebate system that grants the National
Insurance Funds a discount rate paid by pharmaceutical companies. The
purpose of this thesis is to study the role of lobbying (politics of pressure) in the
negotiation and pricing of new drugs

Health Sciences

Pharmaceutical reforms, Impact analysis, Bargaining pressure policies, Pricing

No

0

No

52

107

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/3329570